Works matching IS 03407004 AND DT 2018 AND VI 67 AND IP 3

Results: 13

Acknowledgements.

Published in:: Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 507, doi. 10.1007/s00262-018-2122-3
Publication type:: Article

High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 495, doi. 10.1007/s00262-017-2103-y

By:

Okuma, Yusuke;
Hishima, Tsunekazu;
Kashima, Jumpei;
Homma, Sadamu

Publication type:

Article

Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 341, doi. 10.1007/s00262-017-2099-3

By:

Becker, Jürgen C.;
Stang, Andreas;
Hausen, Axel zur;
Fischer, Nicole;
DeCaprio, James A.;
Tothill, Richard W.;
Lyngaa, Rikke;
Hansen, Ulla Kring;
Ritter, Cathrin;
Nghiem, Paul;
Bichakjian, Christopher K.;
Ugurel, Selma;
Schrama, David

Publication type:

Article

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 471, doi. 10.1007/s00262-017-2098-4

By:

Zhang, Xu-chao;
Cao, Xu;
Sun, Chun;
Xie, Zhi;
Guo, Jian-jun;
Yang, Jin-ji;
Yang, Xue-ning;
Dai, Hang-jun;
Li, Su-chun;
Xu, Xin-ran;
Zuo, Yun-xia;
Chen, Meng;
Koeppen, Hartmut;
He, Jing;
Kiermaier, Astrid;
Shames, David;
Cheng, Gang;
Wu, Yi-long

Publication type:

Article

Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 413, doi. 10.1007/s00262-017-2097-5

By:

Noll, Theresa;
Schultze-Seemann, Susanne;
Kuckuck, Irina;
Michalska, Marta;
Wolf, Philipp

Publication type:

Article

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 445, doi. 10.1007/s00262-017-2095-7

By:

Mehla, Kamiya;
Tremayne, Jarrod;
Grunkemeyer, James A.;
O’Connell, Kelly A.;
Steele, Maria M.;
Caffrey, Thomas C.;
Zhu, Xinyi;
Yu, Fang;
Singh, Pankaj K.;
Schultes, Birgit C.;
Madiyalakan, Ragupathy;
Nicodemus, Christopher F.;
Hollingsworth, Michael A.

Publication type:

Article

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 403, doi. 10.1007/s00262-017-2093-9

By:

Breyer, Johannes;
Wirtz, Ralph M.;
Otto, Wolfgang;
Erben, Philipp;
Worst, Thomas S.;
Stoehr, Robert;
Eckstein, Markus;
Denzinger, Stefan;
Burger, Maximilian;
Hartmann, Arndt

Publication type:

Article

Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 459, doi. 10.1007/s00262-017-2092-x

By:

Suh, Koung Jin;
Kim, Se Hyun;
Kim, Yu Jung;
Kim, Miso;
Keam, Bhumsuk;
Kim, Tae Min;
Kim, Dong-Wan;
Heo, Dae Seog;
Lee, Jong Seok

Publication type:

Article

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 381, doi. 10.1007/s00262-017-2091-y

By:

Briere, David;
Sudhakar, Niranjan;
Woods, David M.;
Hallin, Jill;
Engstrom, Lars D.;
Aranda, Ruth;
Chiang, Harrah;
Sodré, Andressa L.;
Olson, Peter;
Weber, Jeffrey S.;
Christensen, James G.

Publication type:

Article

Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 423, doi. 10.1007/s00262-017-2090-z

By:

Geskin, Larisa J.;
Akilov, Oleg E.;
Kwon, Soonyou;
Schowalter, Michael;
Watkins, Simon;
Whiteside, Theresa L.;
Butterfield, Lisa H.;
Falo, Louis D.

Publication type:

Article

Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 393, doi. 10.1007/s00262-017-2089-5

By:

Zuo, Bai-Le;
Yan, Bo;
Zheng, Guo-Xu;
Xi, Wen-Jin;
Zhang, Xiao;
Yang, An-Gang;
Jia, Lin-Tao

Publication type:

Article

Prophylactic DNA vaccine targeting Foxp3<sup>+</sup> regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 367, doi. 10.1007/s00262-017-2088-6

By:

Namdar, Afshin;
Mirzaei, Reza;
Memarnejadian, Arash;
Boghosian, Roobina;
Samadi, Morteza;
Mirzaei, Hamid Reza;
Farajifard, Hamid;
Zavar, Mehdi;
Azadmanesh, Kayhan;
Elahi, Shokrollah;
Noorbakhsh, Farshid;
Rezaei, Abbas;
Hadjati, Jamshid

Publication type:

Article

Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model.

Published in:

Cancer Immunology, Immunotherapy, 2018, v. 67, n. 3, p. 353, doi. 10.1007/s00262-017-2087-7

By:

Zhang, Yi;
Liu, Zuqiang;
Hao, Xingxing;
Li, Ang;
Zhang, Jiying;
Carey, Cara D.;
Falo, Louis D.;
You, Zhaoyang

Publication type:

Article